{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-089137","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-08-13T20:25:23+00:00","discovered_at":"2026-08-13T20:26:00.320365+00:00","generated_at":"2026-08-13T20:26:43.175550+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nektar Q2 2026: cash $1.02B, net loss $40.6M, Phase 3 ZENITH AD initiated","bullets":["Cash and investments $1,023.4M at June 30, 2026 vs $245.8M at Dec 31, 2025; runway into Q3 2028.","Q2 revenue $10.1M (vs $11.2M); net loss $40.6M ($1.23/share) vs $41.6M ($2.95/share) year-ago.","R&D expense $39.1M (up from $29.9M) on Phase 3 ZENITH AD and manufacturing; G&A down to $12.8M.","Initiated first two Phase 3 ZENITH AD trials in atopic dermatitis in July 2026; BLA submission planned 2029.","April 2026 offering raised $373.8M gross; positive 52-week REZOLVE-AA results announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-089137","json":"https://secwatch.observer/filing/0001213900-26-089137.json","markdown":"https://secwatch.observer/filing/0001213900-26-089137.md","text":"https://secwatch.observer/filing/0001213900-26-089137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/0001213900-26-089137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea0301929-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:26:43.175550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}